tailieunhanh - Apatinib treatment for KIT- and KDR-amplified angiosarcoma: A case report

Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gastric cancer. | Apatinib treatment for KIT- and KDR-amplified angiosarcoma A case report

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN